Results 331 to 340 of about 1,467,646 (404)

The dark sides of the GPCR tree ‐ research progress on understudied GPCRs

British Journal of Pharmacology, Volume 182, Issue 14, Page 3109-3134, July 2025.
Abstract A large portion of the human GPCRome is still in the dark and understudied, consisting even of entire subfamilies of GPCRs such as odorant receptors, class A and C orphans, adhesion GPCRs, Frizzleds and taste receptors. However, it is undeniable that these GPCRs bring an untapped therapeutic potential that should be explored further.
Magdalena M. Scharf, Laura J. Humphrys, Sandra Berndt, Antonella Di Pizio, Juliane Lehmann, Ines Liebscher, Alessandro Nicoli, Masha Y. Niv, Lior Peri, Hannes Schihada, Gunnar Schulte   +10 more
wiley   +1 more source

Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy. [PDF]

J Immunother Cancer
Middelburg J, Schaap G, Sluijter M, Lloyd K, Ovcinnikovs V, Schuurman J, van der Burg SH, Kemper K, van Hall T.   +8 more
europepmc   +1 more source

Pyrotinib and Nab‐Paclitaxel in HER2‐Positive Breast Cancer (PANHER Trial): A Prospective, Single‐Arm, Phase II Trial

Cancer Science, Volume 116, Issue 7, Page 1920-1929, July 2025.
In this multicenter, single‐arm, open‐label phase II trial, patients with HER2‐positive breast cancer who had previously received chemotherapy with taxanes or anthracyclines were enrolled to receive pyrotinib combined with nab‐paclitaxel, and the results demonstrated promising efficacy with an acceptable safety profile.
Huan Li, Min Yan, Zhaohui Li, Xiujie Cui, Xuening Ji, Fengqi Fang, Yuyang Zhang, Yan Wang, Xiangyu Guo, Mingxi Jing, Zhichao Gao, Hui Cao, Fangyuan Dong, Jie Wu, Cui Jiang, Yangyang Duan, Xiaorui Li, Yujun Jiang, Lei Jiang, Ying E, Yufeng Jia, Liang Zhang, Pai Peng, Tao Sun   +23 more
wiley   +1 more source

Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies. [PDF]

Curr Hematol Malig Rep
Keesari PR, Samuels D, Vegivinti CTR, Pulakurthi YS, Kudithi R, Dhar M, Janakiram M.   +6 more
europepmc   +1 more source

Roles and Impacts of Integrative Medical Interventions in Central Nervous System Tumor Treatment: Multi‐Technology Convergence and the Paradigm Shift Toward Functional Reconstruction

CNS Neuroscience &Therapeutics, Volume 31, Issue 7, July 2025.
Multi‐technology interventions (non‐invasive neuromodulation, AI, 3D organoids) for CNS tumor treatment shift from monotherapy to functional reconstruction. They address BBB restriction, tumor heterogeneity, and immune suppression via biological–psychological–technological convergence, enabling precision oncology through dynamic monitoring and ...
Junda Lai, Ketao Liu, Yuhua Lin, Zhonglin Chen, Xianglun Ji, Junkai Wen   +5 more
wiley   +1 more source

A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib. [PDF]

Cell Rep Med
Simoni-Nieves A, Lindzen M, Giri S, Gupta N, Chatterjee R, Selvadurai BR, Van Daele M, Love D, Haga Y, Romaniello D, Salame TM, Zerbib M, Oren R, Tsutsumi Y, Lauriola M, Marrocco I, Yarden Y.   +16 more
europepmc   +1 more source

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients

European Journal of Haematology, Volume 115, Issue 1, Page 16-28, July 2025.
ABSTRACT Relapsed/refractory multiple myeloma (RRMM) research on the impact of +1q abnormalities in real‐world settings is limited. This study evaluated the prognostic and predictive significance of 1q gain [gain(1q)] and amplification [ampl(1q)] in 635 RRMM patients treated with daratumumab‐, elotuzumab‐, and carfilzomib‐based triplet regimens ...
Fortunato Morabito, Enrica Antonia Martino, Monica Galli, Massimo Offidani, Renato Zambello, Sara Bringhen, Nicola Giuliani, Catello Califano, Marino Brunori, Alfredo Gagliardi, Nicola Sgherza, Angela Maria Quinto, Gregorio Barilà, Angelo Belotti, Claudio Cerchione, Gloria Margiotta Casaluci, Raffaele Fontana, Velia Bongarzoni, Giuseppe Tarantini, Daniele Derudas, Francesca Patriarca, Alessandro Gozzetti, Adelina Sementa, Elisabetta Antonioli, Angela Rago, Flavia Lotti, Claudio De Magistris, Maria Teresa Petrucci, Loredana Pettine, Niccolò Bolli, Concetta Conticello, Elena Zamagni, Salvatore Palmieri, Maurizio Musso, Anna Mele, Roberta Della Pepa, Ernesto Vigna, Antonella Bruzzese, Francesca Fazio, Roberto Mina, Laura Paris, Iolanda Donatella Vincelli, Giuliana Farina, Clotilde Cangialosi, Katia Mancuso, Antonietta Pia Falcone, Giuseppe Mele, Antonello Sica, Sonia Morè, Giovanni Reddiconto, Giovanni Tripepi, Graziella D'Arrigo, Emiliano Barbieri, Micol Quaresima, Claudio Salvatore Cartia, Sara Pezzatti, Magda Marcatti, Francesca Farina, Anna Cafro, Michele Palumbo, Valeria Masoni, Virginia Valeria Ferretti, Francesco Di Raimondo, Pellegrino Musto, Antonino Neri, Silvia Mangiacavalli, Massimo Gentile   +66 more
wiley   +1 more source

Structural insight into interleukin-4Rα and interleukin-5 inhibition by nanobodies from a bispecific antibody. [PDF]

MedComm (2020)
Qiu W, Meng J, Su Z, Xie W, Song G.
europepmc   +1 more source

The Arming of Natural Killer Cells With Fc‐Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells

MedComm, Volume 6, Issue 7, July 2025.
Michaël Constantinides, Loïs Coënon, Paolo Falvo, Caroline Multrier, Davide Lombardi, Francesco Bertolini, Pierre Martineau, Bruno Robert, Guillaume Cartron, Martin Villalba   +9 more
wiley   +1 more source

Preliminary Observations on the Efficacy of Efgartigimod Therapy in Autoimmune Nodopathy

European Journal of Neurology, Volume 32, Issue 7, July 2025.
Efgartigimod induced rapid functional improvement in four patients with autoimmune nodopathy, achieving complete remission in anti‐NF186 IgG3+ neuropathy and partial recovery in IgG4‐dominant paranodal subtypes (anti‐NF155/CNTN1+). The kinetics of response were associated with the specific antibody targets and the IgG subclass involved.
Hongfei Tai, Songtao Niu, Hua Pan, Fan Jian, Zhenxian Hu, Na Chen, Ying Wang, Zaiqiang Zhang   +7 more
wiley   +1 more source